Sign in

Jesse Boehm

@boehmjesse.bsky.social
490 followers 155 following 12 posts

Chief Science Officer, Break Through Cancer; Principal Investigator, Koch Institute, MIT - boehmlab.org

PostsRepliesMedia
Jesse Boehm @boehmjesse.bsky.social · 05/08/2026
Hot off the press in Nature! After 10 years, 2,780 patients and 300+ scientists, today we announce the Human Cancer Models Initiative (HCMI) release of 665 organoids and other next generation models! All models and data available to accelerate cancer drug discovery! @nature.com rdcu.be/fx3I3
rdcu.be
A compendium of next-generation patient-derived models for diverse cancers
Nature - The international collaboration of the Human Cancer Models Initiative presents a comprehensive resource of next-generation cancer models from 2,780 donors with 25 cancer types and...
21511
Reposted by Jesse Boehm
Waggoner Lab @labwaggoner.bsky.social · 05/08/2026
Next-generation patient-derived models for diverse cancers @nature.com @broadinstitute.org @boehmjesse.bsky.social @sangerinstitute.bsky.social www.nature.com/articles/s41... www.nature.com/articles/s41... www.nature.com/articles/s41...
051
Reposted by Jesse Boehm
peterwlaird.bsky.social @peterwlaird.bsky.social · 05/08/2026
Very excited to be part of this massive effort to characterize cancer models, revealing strong epigenetic concordance between primary tumors and matched cancer models. rdcu.be/fx3I3
rdcu.be
A compendium of next-generation patient-derived models for diverse cancers
Nature - The international collaboration of the Human Cancer Models Initiative presents a comprehensive resource of next-generation cancer models from 2,780 donors with 25 cancer types and...
151
Reposted by Jesse Boehm
peterwlaird.bsky.social @peterwlaird.bsky.social · 05/08/2026
www.vai.org/article/comp...
vai.org
Compendium of patient-derived models offers new opportunities for cancer research, precision oncology – Van Andel Institute
Read about Compendium of patient-derived models offers new opportunities for cancer research, precision oncology on Van Andel Institute – Stay updated on the latest research and groundbreaking discove...
021
Reposted by Jesse Boehm
Broad Institute @broadinstitute.org · 05/08/2026
The Cancer Dependency Map now includes data from dozens of 3D cancer models across 10 cancer types, revealing new dependencies and offering a more comprehensive resource for cancer research.
broad.io
Cancer Dependency Map now includes next-generation 3D cancer models
Broad scientists expand the DepMap by adding cancer organoids and demonstrate the models’ potential to fuel new discoveries.
142
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 01/07/2026
@boehmjesse.bsky.social will discuss functional precision medicine while also highlighting how Break Through Cancer's model of radical collaboration is helping accelerate progress toward better treatments for patients. Read more about the workshop here: events.cancer.gov/OD/functiona...
events.cancer.gov
Precision in Practice: A Functional Medicine Workshop (Overview) | Events Registration
OverviewBe part of the conversation shaping the future of cancer care at Precision in Practice: A Functional Medicine Workshop on July 1 and 2, 2026! This hybrid event—offered both in person at the…
011
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 01/07/2026
Functional precision medicine has enormous potential to improve how we match the right cancer therapies to the right patients. This week, our Chief Scientific Officer @boehmjesse.bsky.social is participating in the National Cancer Institute's Precision in Practice workshop
111
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 15/04/2026
Congratulations to @boehmjesse.bsky.social, our Chief Science Officer, and @broadinstitute.org's DepMap team on their 2026 @theaacr.bsky.social Scientific Achievement Award. This team is honored for systematically mapping genetic dependencies across cancer cells to uncover specific vulnerabilities
111
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 13/03/2026
𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 and our president Tyler Jacks are featured in @cancerletter.com today. The story highlights our model of Radical Collaboration™ and how we’re aligning institutions and scientists to accelerate progress against the deadliest cancers. cancerletter.com/conversation...
cancerletter.com
Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.” - The Cancer Letter
Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top ti...
022
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 25/02/2026
001
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 25/02/2026
101
Reposted by Jesse Boehm
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break-cancer.bsky.social · 25/02/2026
As we mark five years of Break Through Cancer, we’re posting here for the first time! Five years ago, we asked: What would cancer research look like if collaboration was built into the design? #RadicalCollaboration™ is our answer. These numbers reflect the scale
121
Reposted by Jesse Boehm
Denis Wirtz @deniswirtz.bsky.social · 03/02/2026
Both chambers of Congress have now passed the FY26 minibus with NIH provisions. The President will sign. (1) $48.7 billion for NIH (2) Full IDC recovery (3) No more multi-year funding (4) No NIH reorganization, maintaining the current IC structure.
914762
Reposted by Jesse Boehm
American Association for Cancer Research (AACR) @theaacr.bsky.social · 03/02/2026
We are excited to join The Mark Foundation for Cancer Research, Lustgarten Foundation, Break Through Cancer, and Tina's Wish in a collaboration to solve the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. buff.ly/EAA0knn
132
Reposted by Jesse Boehm
Soragni:Lab @alice.soragnilab.com · 13/12/2025
Long time off this platform.. excited to be back to share that I have been elected President of the @thesfpm.bsky.social alongside @boehmjesse.bsky.social. This community has been a true home for those of us for whom patient-derived models and functional testing belong at the center of cancer care/n
4215
Reposted by Jesse Boehm
Cancer Grand Challenges @cancergrand.bsky.social · 07/11/2025
Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges
042
Jesse Boehm @boehmjesse.bsky.social · 06/11/2025
It was a great discussion! There has never before been so much opportunity to work together to solve the major challenges of our field.
030
Jesse Boehm @boehmjesse.bsky.social · 09/10/2025
We are very proud of our Accelerating GBM Therapies TeamLab for this outstanding, potentially field changing work. We must sample continuously to understand hidden, temporal responses to therapy. Even in the brain.
010
Reposted by Jesse Boehm
Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · 23/08/2025
Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely. The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.
031
Reposted by Jesse Boehm
MIT Koch Institute @mitkochinstitute.bsky.social · 28/04/2025
Be sure to catch Jesse Boehm @boehmjesse.bsky.social in the Tumoroids, Organoids, and Cell Culture session at #AACR25! He’ll present how patient-derived cancer models are shaping research on rare and understudied cancers. 🔗 www.abstractsonline.com/pp8/#!/20273...
multicolored whorls of cell data, resembling ocean currents or fingerprints
051
Reposted by Jesse Boehm
Eric Topol @erictopol.bsky.social · 11/03/2025
Today marks the beginning of OpenRxiv, which replaces bioRxiv and medRxiv, the world's largest preprint platform for life and medical science openrxiv.org/introducing-... @openrxiv.bsky.social
430289
Reposted by Jesse Boehm
Eric Topol @erictopol.bsky.social · 09/03/2025
Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH. Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast. Open-access, w/ transcript, video, no ads erictopol.substack.com/p/anna-greka...
erictopol.substack.com
Anna Greka: Molecular Sleuthing for Rare Diseases
Listen now | Finding the Mechanisms and the Basis for Potential Cures
331275
Reposted by Jesse Boehm
Eric Topol @erictopol.bsky.social · 01/03/2025
3 points of progress vs pancreatic cancer! 1. Neoantigen vaccines www.nature.com/articles/s41... 2. KRAS drugs www.wsj.com/health/healt... 3. Early diagnosis www.science.org/doi/10.1126/...
841384
Reposted by Jesse Boehm
Eric Topol @erictopol.bsky.social · 01/03/2025
Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter www.nytimes.com/2025/03/01/u...
6131251381
Reposted by Jesse Boehm
Dana-Farber News @danafarbernews.bsky.social · 26/02/2025
“The rare tumor space is an example of where we should think hard about the quality data that we have and how we can help inform future treatments,” @danafarber.bsky.social’s Suzanne George, MD, shared at #RareDiseaseSummit 2025.
Suzanne George, MD
073
Reposted by Jesse Boehm
Magdalena Skipper @magdalenaskipper.bsky.social · 25/02/2025
Inexplicably, US administration has launched an unprecedented assault on science, on research institutions & on vital international organizations & initiatives. An assault on science anywhere is an assault on science everywhere; the global community must unite 🧪 www.nature.com/articles/d41...
nature.com
Trump 2.0: an assault on science anywhere is an assault on science everywhere
US President Donald Trump is taking a wrecking ball to science and to international institutions. The global research community must take a stand against these attacks.
13363193
Jesse Boehm @boehmjesse.bsky.social · 22/02/2025
Excited to be speaking this Tuesday, Feb. 25 at #RareDiseaseSummit 2025, @GlobeEvent’s inaugural summit focused on innovation and advocacy in rare disease, “From Bench to Bedside: Rare Cancer Innovations.” Sign up to join in person or virtually: @bostonglobe.com rarediseasesummit2025.splashthat.com
031
Reposted by Jesse Boehm
The Cancer Dependency Map @depmap.org · 05/02/2025
Exciting new synthetic lethal target emerging from #depmap data 🧪🧬 Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L Congratulations to the DepMap team! @vazquezf.bsky.social #depmap #cancertarget #syntheticlethal
nature.com
SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature
Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...
035
Reposted by Jesse Boehm
Francisca Vazquez PhD @vazquezf.bsky.social · 06/02/2025
(1/3) Excited to share our latest work using @depmap.org to uncover a new synthetic lethality in two distinct patient populations! We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO #CancerResearch #SyntheticLethality #Genomics #DepMap
nature.com
SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature
Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...
1136
Reposted by Jesse Boehm
E John Wherry @ejohnwherry.bsky.social · 08/02/2025
A full attack on US science means the red & blue lines will soon cross. Scientists just want science to progress to help society. This administration - and "Pres Musk" - is telling us they don't need/want US science. We will see many of our great ideas and innovation will go to China and elsewhere
32512
Reposted by Jesse Boehm
The Washington Post @washingtonpost.com · 08/02/2025
Breaking news: The Trump administration cut billions in biomedical funding. Researchers say it imperils work on cancer and other illnesses.
washingtonpost.com
NIH cuts billions of dollars in biomedical funding, effective immediately
The move halts a large slice of money for most universities and research institutions virtually overnight, imperiling vital research in everything from cancer to heart disease.
114683342
Reposted by Jesse Boehm
Science Magazine @science.org · 08/02/2025
The National Institutes of Health plans to severely cut the percentage of its grant money that can be used for overhead costs rather than research.
scim.ag
NIH slashes overhead payments for research, sparking outrage
Move to cut indirect cost rate to 15% could cost universities billions of dollars
11181100
Reposted by Jesse Boehm
E John Wherry @ejohnwherry.bsky.social · 08/02/2025
This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this? grants.nih.gov/grants/guide...
grants.nih.gov
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
710934
Jesse Boehm @boehmjesse.bsky.social · 07/02/2025
This!
130
Reposted by Jesse Boehm
Trudy G. Oliver @tgoliver.bsky.social · 05/02/2025
Thank you #AACR for your strong support of #cancer researchers and the people who do that work! www.aacr.org/about-the-aa...
aacr.org
AACR Statement on the New Administration’s Recent Executive Orders and Policy Proposals
The American Association for Cancer Research (AACR) is increasingly concerned about the numerous executive orders and policy proposals that the new administration has issued during the first two weeks...
0186
Jesse Boehm @boehmjesse.bsky.social · 29/01/2025
It's time to tackle rare cancers together - both a scientific opportunity and a moral imperative! I've shared a few brief thoughts in the Trends in Cancer opinions perspective on this topic - out now online www.cell.com/trends/cance...
cell.com
Think zebras: challenges and opportunities for treating rare cancers
The adage goes, ‘When you hear hoofbeats, think of horses, not zebras’. However, placing less emphasis on ‘zebras’ – both in the clinical and research space – can prevent many rare cancers from being ...
031
Reposted by Jesse Boehm
JT Neal @jtneal.bsky.social · 27/01/2025
So, we teamed up with Anne and Paul’s lab, along with Calvin Jan at Calico, with the aim of building an accessible & unbiased high-content cell profiling platform that could be applied to genome-scale CRISPR screens (Project PERISCOPE).
PERISCOPE logo
PERISCOPE Acronym: Perturbation Effect Readout In situ via Single-cell optical phenotyping (yeah it's a mouthful)
121
Reposted by Jesse Boehm
JT Neal @jtneal.bsky.social · 27/01/2025
We’re big fans of using expression-based profiling (specifically Perturb-seq) to generate high-dimensional phenotypic profiles of perturbed cells, and w/ @oana-ursu.bsky.social & @boehmjesse.bsky.social have used it successfully for generating variant effect maps (www.nature.com/articles/s41...)
nature.com
Massively parallel phenotyping of coding variants in cancer with Perturb-seq - Nature Biotechnology
The functional impact of somatic mutations in cancer genes is determined by pooled Perturb-seq.
111
Reposted by Jesse Boehm
JT Neal @jtneal.bsky.social · 27/01/2025
Our paper “A genome-wide atlas of human cell morphology” is finally out today in @naturemethods.bsky.social ! www.nature.com/articles/s41... (I tweeted about our preprint in 2023 over at the bad place, but deactivated my account, so here we go again!)
nature.com
A genome-wide atlas of human cell morphology - Nature Methods
An optical pooled cell profiling platform (PERISCOPE) based on Cell Painting and optical sequencing of molecular barcodes was used to develop the first unbiased genome-wide morphology-based perturbati...
213939
Reposted by Jesse Boehm
E John Wherry @ejohnwherry.bsky.social · 23/01/2025
Yes. Exactly. One of (if not THE) best ROI for any govt spending.
24519
Reposted by Jesse Boehm
Eli Van Allen @vanallenlab.bsky.social · 02/01/2025
Here's our latest, led by Drs. Riaz Gillani & Ryan Collins - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids: @danafarber.bsky.social @bostonchildrens.bsky.social @broadinstitute.org @science.org www.science.org/doi/10.1126/...
science.org
Rare germline structural variants increase risk for pediatric solid tumors
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using ge...
34719
Reposted by Jesse Boehm
peterwlaird.bsky.social @peterwlaird.bsky.social · 02/01/2025
Thrilled to share the results in Cancer Cell of years of hard work to develop classifiers for all major TCGA cancer subtypes, enabling assessment of differential drug response among cancer subtypes in clinical trials. www.cell.com/cancer-cell/...
cell.com
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
Ellrott et al. provide a means to assign patient samples from clinical trials and other cancer genome studies to published TCGA molecular subtypes. Applying machine learning to data from five different molecular platforms for 8,791 TCGA tumor samples, they contribute a public resource of 737 top classifier models, which can form the foundation for clinical assay development.
0139
Jesse Boehm @boehmjesse.bsky.social · 02/12/2024
Looking forward to delivering keynote address at the #slas2025 meeting January 25 - 29, 2025 (San Diego, CA, USA). I will share thoughts on current and future state of precision functional genomics to drive precision medicine forward. San Diego sunshine guaranteed! www.slas.org/publications...
slas.org
Curiosity Ignites Anticipation for SLAS2025!
Find it all under one roof – 150 speakers, eight life sciences educational tracks, new features, events and a host of colleagues. The SLAS International Exhibition and Conference, to be held Jan...
061